Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease
- Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare autosomal recessive lysosomal storage disease.
- This neurodegenerative disorder usually presents between ages 2 and 4 years with psychomotor decline, seizures, and vision loss which progress to a vegetative state and death in the 2nd decade of life (1).
- Synonym(s): Jansky-Bielschowsky disease; late-infantile neuronal ceroid lipofuscinosis (NCL); late-infantile Batten disease
- Worldwide reported incidence estimates range from 0.22 to 9 per 100,000 live births (1).
- In the United States, CLN2 occurs in an estimated 2 to 4 of every 100,000 live births.
CLN2 has an estimated prevalence of 0.6 to 0.7 per million inhabitants worldwide.
Etiology and Pathophysiology
- CLN2 is caused by deficiency of the enzyme tripeptidyl peptidase 1 (TPP1), leading to the lysosomal accumulation of an autofluorescent lipopigment with subsequent neuronal degeneration of the hippocampus, cortical interneurons, cerebellum, and thalamocortical neurons (1,2).
- TPP1 cleaves tripeptides from the N-terminus of diverse partially unfolded lysosomal proteins; however, the in vivo substrates of TPP1 are unknown.
- The mechanism by which failure to cleave these N-terminal peptides leads to neuronal death and the clinical manifestations seen in CLN2 is poorly understood.
- This disorder is caused by mutations in the TPP1/CLN2 gene located in chromosome 11p15.4 (OMIM 204500).
- The two most common mutations found in patients with CLN2 are c.509-1G>C, a splicing mutation, and c.622C>T (R208X), which results in the introduction of a termination codon prematurely.
- Prenatal diagnosis is an option in patients with family history of CLN2 or known carriers.
- Genetic counseling should be offered to family members and the risk of CLN2 should be assessed for subsequent pregnancies.
Commonly Associated Conditions
- Epilepsy is present in 75% of children with CLN2, usually diagnosed between age 2 and 4 years.
- Perioperative hypothermia secondary to impaired thermoregulation in the setting of autonomic nerve dysfunction is common.
- Cardiac conduction defects, tachyarrhythmias, and sudden cardiac death have been reported.
There's more to see -- the rest of this topic is available only to subscribers.
Domino, Frank J., et al., editors. "Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease." 5-Minute Clinical Consult, 27th ed., Wolters Kluwer, 2020. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688616/all/Neuronal_Ceroid_Lipofuscinosis_Type_2__CLN2__Disease.
Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease. In: Domino FJF, Baldor RAR, Golding JJ, et al, eds. 5-Minute Clinical Consult. Wolters Kluwer; 2020. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688616/all/Neuronal_Ceroid_Lipofuscinosis_Type_2__CLN2__Disease. Accessed May 29, 2023.
Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease. (2020). In Domino, F. J., Baldor, R. A., Golding, J., & Stephens, M. B. (Eds.), 5-Minute Clinical Consult (27th ed.). Wolters Kluwer. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688616/all/Neuronal_Ceroid_Lipofuscinosis_Type_2__CLN2__Disease
Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease [Internet]. In: Domino FJF, Baldor RAR, Golding JJ, Stephens MBM, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2020. [cited 2023 May 29]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688616/all/Neuronal_Ceroid_Lipofuscinosis_Type_2__CLN2__Disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease ID - 1688616 ED - Domino,Frank J, ED - Baldor,Robert A, ED - Golding,Jeremy, ED - Stephens,Mark B, BT - 5-Minute Clinical Consult, Updating UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688616/all/Neuronal_Ceroid_Lipofuscinosis_Type_2__CLN2__Disease PB - Wolters Kluwer ET - 27 DB - Medicine Central DP - Unbound Medicine ER -